特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
934750

ヒトインスリンの世界市場:2025年までの適応症別、ブランド別、投与経路別、種 類別、作用発現時間別、製品別、地域別の予測と機会

Global Human Insulin Market By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025

出版日: | 発行: TechSci Research | ページ情報: 英文 121 Pages | 納期: お問合せ

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

ヒトインスリンの世界市場:2025年までの適応症別、ブランド別、投与経路別、種 類別、作用発現時間別、製品別、地域別の予測と機会
出版日: 2020年05月01日
発行: TechSci Research
ページ情報: 英文 121 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 目次
概要

当レポートは、世界の人インスリン市場を調査したもので、各地域市場の展望 、市場の力学、主なトレンド、競合情勢などの情報を提供するとともに、戦略的提 言を示しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 世界のヒトインスリン市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 顧客の声

第6章 ヒトインスリン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 適応症別(I型糖尿病、II型糖尿病)
    • ブランド別(フムリンR、ノボリンR、フムリンN、エクスベラ、アフレザ、ノ ボリンN)
    • 投与経路別(皮下、経鼻、静脈内、経皮、経口、その他)
    • タイプ別(基礎、ボーラス、プレミックス、バイオシミラー、トラディショナ ル)
    • 作用発現時間別(急速作用、短時間作用、中間作用、長時間作用、超長時間作 用、混合前、吸入)
    • 製品別(インスリンペン、インスリンポンプ、注入システム、注射)
    • 会社別(2019)
    • 地域別
  • 市場魅力指数

第7章 アジア太平洋の人間のインスリン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 適応症別
    • ブランド別
    • 投与経路別
    • タイプ別
    • 作用発現時間別
    • 製品別
    • 国別
  • 市場魅力指数
  • アジア太平洋地域:国分析
    • 中国のヒトインスリン市場の展望
    • インドのヒトインスリン市場の展望
    • 日本におけるヒトインスリン市場の展望
    • 韓国のヒトインスリン市場の展望
    • シンガポールのヒトインスリン市場の展望
    • オーストラリアのヒトインスリン市場の展望

第8章 欧州のヒトインスリンの市場の展望

  • 市場規模と予測
    • 値とボリューム
  • 市場シェアと予測
    • 適応症別
    • ブランド別
    • 投与経路別
    • タイプ別
    • 作用発現時間別
    • 製品別
    • 国別
  • 市場魅力指数
  • 欧州:国分析
    • フランスのヒトインスリン市場の展望
    • ドイツのヒトインスリン市場の展望
    • 英国のヒトインスリン市場の展望
    • イタリアのヒトインスリン市場の展望
    • ロシアのヒトインスリン市場の展望
    • スペインのヒトインスリン市場の展望

第9章 北米のヒトインスリンの市場の展望

  • 市場規模と予測
    • 値とボリューム
  • 市場シェアと予測
    • 適応症別
    • ブランド別
    • 投与経路別
    • タイプ別
    • 作用発現時間別
    • 製品別
    • 国別
  • 市場魅力指数
  • 北米:国分析
    • 米国のヒトインスリン市場の展望
    • メキシコのヒトインスリン市場の展望
    • カナダのヒトインスリン市場の展望

第10章 南アメリカの人間のインスリン市場の展望

  • 市場規模と予測
    • 値とボリューム
  • 市場シェアと予測
    • 適応症別
    • ブランド別
    • 投与経路別
    • タイプ別
    • 作用発現時間別
    • 製品別
    • 国別
  • 市場魅力指数
  • 南米:国分析
    • ブラジルのヒトインスリン市場の展望
    • アルゼンチンのヒトインスリン市場の展望
    • コロンビアのヒトインスリン市場の展望

第11章 中東およびアフリカの人間のインスリン市場の展望

  • 市場規模と予測
    • 値とボリューム
  • 市場シェアと予測
    • 適応症別
    • ブランド別
    • 投与経路別
    • タイプ別
    • 作用発現時間別
    • 製品別
    • 国別
  • 市場魅力指数
  • 中東・アフリカ地域:国分析
    • 南アフリカのヒトインスリン市場の展望
    • サウジアラビアのヒトインスリン市場の見通し
    • UAEヒトインスリン市場の展望

第12章 市場力学

  • 促進要因
  • 挑戦

第13章 市場動向

第14章 競合情勢

  • 競合の展望
  • 主要企業のプロファイル
    • Nektar Therapeutics
    • MannKind Corporation
    • Novo Nordisk
    • Physicians Total Care, Inc.
    • Eli Lilly and Company
    • A-S Medication Solutions
    • REMEDYREPACK INC.
    • Sedico Co.
    • Sanofi Aventis
    • Pfizer Inc.
    • PerkinElmer
    • Merck
    • Biocon
    • Wockhardt
    • Julphal
    • Ypsomed AG
    • Becton Dickinson and Company
    • B. Braun Melsungen AG
    • Baxter
    • Tandem Diabetes Care, Inc.

第15章 戦略的推奨事項

第16章 免責事項

目次
Product Code: 4637

Global human insulin market is expected to grow at a steady CAGR during forecast period. Growing geriatric population and increasing incidents of diabetic cases around globe are contributing to the growing demand for human insulin market, globally. Now a days, diabetes is not only restricted to geriatric population, but it is also common among youth. Also, the technological advancements have eradicated human physical activities leading to obesity and diabetes disorders which is directly influencing the growth of the market. Cost effectiveness can be considered as a major restraining factor for the market as everyone suffering from diabetes might not be able to afford insulin.

The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products and region. Based on indication, market can be bifurcated into type I diabetes and type II diabetes. Type II diabetes is likely to hold the largest market share until 2025 as around 90% of the overall population has type II diabetes.

Based on regional analysis, North America dominated the human insulin market in 2019 due to large population base suffering from diabetes and presence of leading companies in countries like US and Canada.

Leading players in the global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk, Physicians Total Care, Inc., Eli Lilly and Company, A-S Medication Solutions, REMEDYREPACK INC., Sedico Co., Sanofi Aventis, Pfizer Inc., PerkinElmer, Merck, Biocon, Wockhardt, Julphal, Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter and Tandem Diabetes Care, Inc., among others.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and forecast the market size of global human insulin market.
  • To classify and forecast global human insulin market based on indication, brand, route of administration, type, onset type, products and region.
  • To identify drivers and challenges for global human insulin market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global human insulin market.
  • To conduct pricing analysis for global human insulin market.
  • To identify and analyze the profile of leading players operating in global human insulin market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of hospitals/clinics across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the hospitals/clinics which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals/clinics and presence of all major players across the globe.

TechSci Research calculated the market size of global human insulin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Hospitals/clinics, research institutes and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to human insulin
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals/clinics, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global human insulin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Indication:

Type I Diabetes

Type II Diabetes

  • Market, By Brand:

Humulin R

Novolin R

Humulin N

Exubera

Afrezza

Novolin N

  • Market, By Route of Administration:

Subcutaneous

Nasal

Intravenous

Transdermal

Oral

Others

  • Market, By Type:

Basal

Bolus

Pre-mixed

Biosimilar

Traditional

  • Market, By Onset Time:

Rapid acting

Short-acting,

Intermediate acting

Long acting

Ultra-long acting

Pre-mixed

Inhaled

  • Market, By Products:

Insulin Pens

Insulin Pumps

Infusion System

Injection

  • Market, By Region:

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Singapore
  • Australia

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Russia
  • Spain

North America

  • United States
  • Mexico
  • Canada

South America

  • Brazil
  • Argentina
  • Colombia

Middle east & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global human insulin market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Human Insulin Market

4. Executive Summary

5. Voice of Customer

6. Global Human Insulin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Type I Diabetes, Type II Diabetes)
    • 6.2.2. By Brand (Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N)
    • 6.2.3. By Route of administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others)
    • 6.2.4. By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
    • 6.2.5. By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
    • 6.2.6. By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection)
    • 6.2.7. By Company (2019)
    • 6.2.8. By Region
  • 6.3. Market Attractiveness Index

7. Asia-Pacific Human Insulin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Brand
    • 7.2.3. By Route of Administration
    • 7.2.4. By Type
    • 7.2.5. By Onset Time
    • 7.2.6. By Products
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Asia-Pacific: Country Analysis
    • 7.4.1. China Human Insulin Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Indication
        • 7.4.1.2.2. By Brand
        • 7.4.1.2.3. By Route of Administration
        • 7.4.1.2.4. By Type
        • 7.4.1.2.5. By Onset Time
        • 7.4.1.2.6. By Products
    • 7.4.2. India Human Insulin Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Indication
        • 7.4.2.2.2. By Brand
        • 7.4.2.2.3. By Route of Administration
        • 7.4.2.2.4. By Type
        • 7.4.2.2.5. By Onset Time
        • 7.4.2.2.6. By Products
    • 7.4.3. Japan Human Insulin Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Indication
        • 7.4.3.2.2. By Brand
        • 7.4.3.2.3. By Route of Administration
        • 7.4.3.2.4. By Type
        • 7.4.3.2.5. By Onset Time
        • 7.4.3.2.6. By Products
    • 7.4.4. South Korea Human Insulin Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Indication
        • 7.4.4.2.2. By Brand
        • 7.4.4.2.3. By Route of Administration
        • 7.4.4.2.4. By Type
        • 7.4.4.2.5. By Onset Time
        • 7.4.4.2.6. By Products
    • 7.4.5. Singapore Human Insulin Market Outlook
      • 7.4.5.1. Market Size & Forecast
        • 7.4.5.1.1. By Value
      • 7.4.5.2. Market Share & Forecast
        • 7.4.5.2.1. By Indication
        • 7.4.5.2.2. By Brand
        • 7.4.5.2.3. By Route of Administration
        • 7.4.5.2.4. By Type
        • 7.4.5.2.5. By Onset Time
        • 7.4.5.2.6. By Products
    • 7.4.6. Australia Human Insulin Market Outlook
      • 7.4.6.1. Market Size & Forecast
        • 7.4.6.1.1. By Value
      • 7.4.6.2. Market Share & Forecast
        • 7.4.6.2.1. By Indication
        • 7.4.6.2.2. By Brand
        • 7.4.6.2.3. By Route of Administration
        • 7.4.6.2.4. By Type
        • 7.4.6.2.5. By Onset Time
        • 7.4.6.2.6. By Products

8. Europe Human Insulin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Brand
    • 8.2.3. By Route of Administration
    • 8.2.4. By Type
    • 8.2.5. By Onset Time
    • 8.2.6. By Products
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. Europe: Country Analysis
    • 8.4.1. France Human Insulin Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Indication
        • 8.4.1.2.2. By Brand
        • 8.4.1.2.3. By Route of Administration
        • 8.4.1.2.4. By Type
        • 8.4.1.2.5. By Onset Time
        • 8.4.1.2.6. By Products
    • 8.4.2. Germany Human Insulin Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Indication
        • 8.4.2.2.2. By Brand
        • 8.4.2.2.3. By Route of Administration
        • 8.4.2.2.4. By Type
        • 8.4.2.2.5. By Onset Time
        • 8.4.2.2.6. By Products
    • 8.4.3. United Kingdom Human Insulin Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Indication
        • 8.4.3.2.2. By Brand
        • 8.4.3.2.3. By Route of Administration
        • 8.4.3.2.4. By Type
        • 8.4.3.2.5. By Onset Time
        • 8.4.3.2.6. By Products
    • 8.4.4. Italy Human Insulin Market Outlook
      • 8.4.4.1. Market Size & Forecast
        • 8.4.4.1.1. By Value
      • 8.4.4.2. Market Share & Forecast
        • 8.4.4.2.1. By Indication
        • 8.4.4.2.2. By Brand
        • 8.4.4.2.3. By Route of Administration
        • 8.4.4.2.4. By Type
        • 8.4.4.2.5. By Onset Time
        • 8.4.4.2.6. By Products
    • 8.4.5. Russia Human Insulin Market Outlook
      • 8.4.5.1. Market Size & Forecast
        • 8.4.5.1.1. By Value
      • 8.4.5.2. Market Share & Forecast
        • 8.4.5.2.1. By Indication
        • 8.4.5.2.2. By Brand
        • 8.4.5.2.3. By Route of Administration
        • 8.4.5.2.4. By Type
        • 8.4.5.2.5. By Onset Time
        • 8.4.5.2.6. By Products
    • 8.4.6. Spain Human Insulin Market Outlook
      • 8.4.6.1. Market Size & Forecast
        • 8.4.6.1.1. By Value
      • 8.4.6.2. Market Share & Forecast
        • 8.4.6.2.1. By Indication
        • 8.4.6.2.2. By Brand
        • 8.4.6.2.3. By Route of Administration
        • 8.4.6.2.4. By Type
        • 8.4.6.2.5. By Onset Time
        • 8.4.6.2.6. By Products

9. North America Human Insulin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Brand
    • 9.2.3. By Route of Administration
    • 9.2.4. By Type
    • 9.2.5. By Onset Time
    • 9.2.6. By Products
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. North America: Country Analysis
    • 9.4.1. United States Human Insulin Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Indication
        • 9.4.1.2.2. By Brand
        • 9.4.1.2.3. By Route of Administration
        • 9.4.1.2.4. By Type
        • 9.4.1.2.5. By Onset Time
        • 9.4.1.2.6. By Products
    • 9.4.2. Mexico Human Insulin Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Indication
        • 9.4.2.2.2. By Brand
        • 9.4.2.2.3. By Route of Administration
        • 9.4.2.2.4. By Type
        • 9.4.2.2.5. By Onset Time
        • 9.4.2.2.6. By Products
    • 9.4.3. Canada Human Insulin Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Indication
        • 9.4.3.2.2. By Brand
        • 9.4.3.2.3. By Route of Administration
        • 9.4.3.2.4. By Type
        • 9.4.3.2.5. By Onset Time
        • 9.4.3.2.6. By Products

10. South America Human Insulin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Brand
    • 10.2.3. By Route of Administration
    • 10.2.4. By Type
    • 10.2.5. By Onset Time
    • 10.2.6. By Products
    • 10.2.7. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. South America: Country Analysis
    • 10.4.1. Brazil Human Insulin Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Indication
        • 10.4.1.2.2. By Brand
        • 10.4.1.2.3. By Route of Administration
        • 10.4.1.2.4. By Type
        • 10.4.1.2.5. By Onset Time
        • 10.4.1.2.6. By Products
    • 10.4.2. Argentina Human Insulin Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Indication
        • 10.4.2.2.2. By Brand
        • 10.4.2.2.3. By Route of Administration
        • 10.4.2.2.4. By Type
        • 10.4.2.2.5. By Onset Time
        • 10.4.2.2.6. By Products
    • 10.4.3. Colombia Human Insulin Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Indication
        • 10.4.3.2.2. By Brand
        • 10.4.3.2.3. By Route of Administration
        • 10.4.3.2.4. By Type
        • 10.4.3.2.5. By Onset Time
        • 10.4.3.2.6. By Products

11. Middle East and Africa Human Insulin Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Brand
    • 11.2.3. By Route of Administration
    • 11.2.4. By Type
    • 11.2.5. By Onset Time
    • 11.2.6. By Products
    • 11.2.7. By Country
  • 11.3. Market Attractiveness Index
  • 11.4. MEA: Country Analysis
    • 11.4.1. South Africa Human Insulin Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Indication
        • 11.4.1.2.2. By Brand
        • 11.4.1.2.3. By Route of Administration
        • 11.4.1.2.4. By Type
        • 11.4.1.2.5. By Onset Time
        • 11.4.1.2.6. By Products
    • 11.4.2. Saudi Arabia Human Insulin Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Indication
        • 11.4.2.2.2. By Brand
        • 11.4.2.2.3. By Route of Administration
        • 11.4.2.2.4. By Type
        • 11.4.2.2.5. By Onset Time
        • 11.4.2.2.6. By Products
    • 11.4.3. UAE Human Insulin Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Indication
        • 11.4.3.2.2. By Brand
        • 11.4.3.2.3. By Route of Administration
        • 11.4.3.2.4. By Type
        • 11.4.3.2.5. By Onset Time
        • 11.4.3.2.6. By Products

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. Nektar Therapeutics
    • 14.2.2. MannKind Corporation
    • 14.2.3. Novo Nordisk
    • 14.2.4. Physicians Total Care, Inc.
    • 14.2.5. Eli Lilly and Company
    • 14.2.6. A-S Medication Solutions
    • 14.2.7. REMEDYREPACK INC.
    • 14.2.8. Sedico Co.
    • 14.2.9. Sanofi Aventis
    • 14.2.10. Pfizer Inc.
    • 14.2.11. PerkinElmer
    • 14.2.12. Merck
    • 14.2.13. Biocon
    • 14.2.14. Wockhardt
    • 14.2.15. Julphal
    • 14.2.16. Ypsomed AG
    • 14.2.17. Becton Dickinson and Company
    • 14.2.18. B. Braun Melsungen AG
    • 14.2.19. Baxter
    • 14.2.20. Tandem Diabetes Care, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.